[Hepatitis C and HIV coinfection. Current aspects of therapy].
HIV/HCV coinfection is characterized by a progredient course of hepatitis C. A more rapid development to cirrhosis, and especially in the presence of progredient immunodeficiency, an increased mortality due to liver failure has been described in coinfected patients. In addition hepatitis C has an unfavorable impact on the progression of HIV. The worse course of hepatitis C in HIV-coinfected patients as well as the faster progression of HIV underline the need for development of treatment options for hepatitis C in HIV-coinfected patients. First results from trials looking at the effect of pegylated interferon and ribavirin for treatment of hepatitis C in HIV-coinfected patients found primary response rates of around 50% which were clearly better than the response rates observed under non-modified interferon/ribavirin therapy in HIV/HCV-coinfected patients so far.
Rockstroh
J K
JK
Universitätsklinik und Poliklinik I, Universitätsklinikum Bonn. rockstroh@uni-bonn.de
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
D019380:Anti-HIV Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; C100416:peginterferon alfa-2a